Bioventus has acquired BioStructures, adding its entire line of products to its portfolio, as well as its research and development pipeline. Employees of BioStructures will be given offers to join Bioventus.
The BioStructures product portfolio includes synthetic, allograft, collagen, and demineralised bone matrix (DBM) options for surgeons. Its products include Interface Bioactive Bonegraft and Signafuse Bioactive Bonegraft Putty.
Tony Bihl, CEO of Bioventus, says, “This now gives Bioventus a broad offering of bone grafting solutions backed by clinical and technical data to benefit patients, surgeons, and hospitals.”
Bioventus will continue to work with the current network of distributors carrying the BioStructures product portfolio and try to expand that sales footprint to bring these solutions to more surgeons and hospitals throughout the US.